Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 2/20 | 0.30 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16975518 | 0.84 | LRRK2 (0.49) | LRRK2ALOX15 | |
| SCHEMBL5021101 | 0.80 | LRRK2 (0.39) | LRRK2ALOX15FLT3MAP3K1PI4KB | |
| SCHEMBL28563034 | 0.80 | LRRK2 (0.39) | LRRK2ALOX15FLT3MAP3K1PI4KB | |
| SCHEMBL16985380 | 0.78 | ALDH1A1 (0.35) | LRRK2 | |
| SCHEMBL5021081 | 0.76 | LRRK2 (0.43) | LRRK2ALOX15 | |
| SCHEMBL4561032 | 0.76 | LRRK2 (0.40) | LRRK2ALOX15 | |
| SCHEMBL7886091 | 0.75 | PKM (0.39) | LRRK2FLT3MAP3K1PI4KB | |
| SCHEMBL7886096 | 0.75 | PKM (0.39) | LRRK2FLT3MAP3K1PI4KB | |
| SCHEMBL16985277 | 0.75 | JAK1 (0.39) | LRRK2ALOX15FLT3MAP3K1PI4KB | |
| SCHEMBL7884509 | 0.74 | PDE4B (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | LRRK2, PARK7, PINK1 | LRRK2 1/4885ALOX15 2733/4885FLT3 4319/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | LRRK2 1/4885ALOX15 2529/4885FLT3 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.